Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis

Authors: Jianming Liu, Qiande Liao, Yangde Zhang, Shenghua Sun, Caigao Zhong, Xinmin Liu

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

Many studies have investigated the association between Cyclin D1 (CCND1) G870A polymorphism and lung cancer risk, but the impact of CCND G870A polymorphism on lung cancer is unclear owing to the obvious inconsistence among those studies. This study aimed to quantify the strength of association between CCND1 G870A polymorphism and lung cancer risk. We searched the PubMed, Embase, and Wangfang databases for articles on studies relating the CCND1 G870A polymorphism to the risk of lung cancer in humans. We estimated summary odds ratios (ORs) with their confidence intervals (CIs) to assess the association. Meta-analyses of total studies showed that CCND1 G870A polymorphism was associated with lung cancer risk under three genetic models (ORA versus G = 1.13, 95 % CI 1.03–1.24; ORAA versus GG = 1.20, 95 % CI 1.07–1.35; ORAA versus AG + GG = 1.23, 95 % CI 1.02–1.50). Meta-analyses of studies with high quality showed that CCND1 G870A polymorphism was associated with lung cancer risk under two genetic models (ORA versus G = 1.08, 95 % CI 1.02–1.15; ORAA versus GG = 1.17, 95 % CI 1.04–1.32). Subgroup analyses by ethnicity and sensitivity analyses further identified the significant association above. No evidence of publication bias was observed. Meta-analyses of available data show a significant association between the CCND1 G870A polymorphism and lung cancer risk, and CCND1 G870A polymorphic variant A contributes to increased risk of lung cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.CrossRefPubMed
3.
4.
Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12:399–408.CrossRefPubMed
5.
Steliga MA, Dresler CM. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. Surg Oncol Clin N Am. 2011;20:605–18.CrossRefPubMed
6.
Yokota J, Shiraishi K, Kohno T. Genetic basis for susceptibility to lung cancer: recent progress and future directions. Adv Cancer Res. 2010;109:51–72.CrossRefPubMed
7.
8.
Herber B, Truss M, Beato M, Muller R. Inducible regulatory elements in the human cyclin d1 promoter. Oncogene. 1994;9:1295–304.PubMed
9.
10.
Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–31.CrossRefPubMed
11.
Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin d1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620–8.CrossRefPubMed
12.
Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin d1 isoform, cyclin d1b, is a nuclear oncogene. Cancer Res. 2003;63:7056–61.PubMed
13.
Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES. Cyclin d1 splice variants. Differential effects on localization, rb phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339–47.CrossRefPubMed
14.
Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC. Cyclin d1 (ccnd1) a870g gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (nsclc) patients. Lung Cancer. 2006;51:303–11.CrossRefPubMed
15.
Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X. Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007;13:5974–81.CrossRefPubMed
16.
Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin d1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24:1499–503.CrossRefPubMed
17.
Hung RJ, Boffetta P, Canzian F, Moullan N, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Landi S, Gemignani F, Hall J, Brennan P. Sequence variants in cell cycle control pathway, X-ray exposure, and lung cancer risk: a multicenter case–control study in Central Europe. Cancer Res. 2006;66:8280–6.CrossRefPubMed
18.
Sobti RC, Kaur P, Kaur S, Singh J, Janmeja AK, Jindal SK, Kishan J, Raimondi S. Effects of cyclin d1 (ccnd1) polymorphism on susceptibility to lung cancer in a north Indian population. Cancer Genet Cytogenet. 2006;170:108–14.CrossRefPubMed
19.
Hsia TC, Liu CJ, Lin CH, Chang WS, Chu CC, Hang LW, Lee HZ, Lo WC, Bau DT. Interaction of ccnd1 genotype and smoking habit in Taiwan lung cancer patients. Anticancer Res. 2011;31:3601–5.PubMed
20.
Attia J, Thakkinstian A, D’Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol. 2003;56:297–303.CrossRefPubMed
21.
Petitti DB. Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine (2nd ed). New York: Oxford University Press; 2000.
22.
Sotiriadis A, Makrigiannakis A, Stefos T, Paraskevaidis E, Kalantaridou SN. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol. 2007;109:1146–55.CrossRefPubMed
23.
Su MT, Lin SH, Chen YC. Genetic association studies of angiogenesis- and vasoconstriction-related genes in women with recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod Updat. 2011;17:803–12.CrossRef
24.
Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–8.CrossRef
25.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
26.
27.
28.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
29.
Thompson SG, Higgins J. How should meta–regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559–73.CrossRefPubMed
30.
A Tobias Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–17.
31.
Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–5.CrossRefPubMed
32.
33.
Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.CrossRefPubMedPubMedCentral
34.
35.
Wang R, Zhang JH, Li Y, Wen D, Wei L. The association of cyclin d1(a870g)polymorphism with susceptibility to lung cancer in northern Chinese population. Tumor. 2003;23:364–6. Article in Chinese.
36.
Li QP, Deng YJ, Xiao CJ, Yang HS. Comparative study of polymorphism of cyclin dl gene in patients with non small cell lung cancer from Xuanwei and Kunming. Shandong Yi Yao. 2009;49:1–3. Article in Chinese.
37.
Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, Romkes M. Association of polymorphisms in the cyclin d1 and xpd genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005;42:222–8.CrossRefPubMed
38.
Wang Q, Jiang YX, Li GF, Liu X, Wang WW, Deng J, Chen N. The relationship between the cyclin d1(ccndi)a870g gene polymorphism and non small cell lung cancer in Yunnan. Med Philos. 2008;29:36–8. Article in Chinese.
39.
Ma H, Chen J, Pan S, Dai J, Jin G, Hu Z, Shen H, Shu Y. Potentially functional polymorphisms in cell cycle genes and the survival of non-small cell lung cancer in a Chinese population. Lung Cancer. 2011;73:32–7.CrossRefPubMed
40.
Pabalan N, Bapat B, Sung L, Jarjanazi H, Francisco-Pabalan O, Ozcelik H. Cyclin d1 pro241pro (ccnd1-g870a) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomark Prev. 2008;17:2773–81.CrossRef
41.
Betticher DC, Heighway J, Thatcher N, Hasleton PS. Abnormal expression of ccnd1 and rb1 in resection margin epithelia of lung cancer patients. Br J Cancer. 1997;75:1761–8.CrossRefPubMedPubMedCentral
42.
Kim ES, Lee JJ, Wistuba II. Cotargeting cyclin d1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev Res (Phila). 2011;4:779–82.CrossRef
43.
Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin d1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55:1–14.CrossRefPubMed
44.
Olding LB, Thurin J, Svalander C, Koprowski H. Expression of gastrointestinal carcinoma-associated antigen (gica) detected in human fetal tissues by monoclonal antibody ns-19-9. Int J Cancer J Int Du Cancer. 1984;34:187–92.CrossRef
45.
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin d as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–72.CrossRefPubMed
46.
Peters J, Mengersen K. Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof. 2008;31:370–89.CrossRefPubMed
47.
Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209–17.CrossRefPubMed
48.
Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of tp53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer. 2009;66:15–21.CrossRefPubMed
Metadata
Title
Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis
Authors
Jianming Liu
Qiande Liao
Yangde Zhang
Shenghua Sun
Caigao Zhong
Xinmin Liu
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0397-0

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue

Research Article

Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis

Research Article

Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma

Research Article

Nuclear p63 expression in osteoblastic tumors

Research Article

Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC

Research Article

The expression of heparanase and microRNA-1258 in human non-small cell lung cancer

Research Article

Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits